Connection

Lee Chao to Apoptosis

This is a "connection" page, showing publications Lee Chao has written about Apoptosis.
Connection Strength

1.782
  1. Kallistatin: double-edged role in angiogenesis, apoptosis and oxidative stress. Biol Chem. 2017 11 27; 398(12):1309-1317.
    View in: PubMed
    Score: 0.360
  2. Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides. 2007 Jul; 28(7):1383-9.
    View in: PubMed
    Score: 0.174
  3. Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension. 2007 Mar; 49(3):490-7.
    View in: PubMed
    Score: 0.170
  4. Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp Neurol. 2006 Feb; 197(2):521-30.
    View in: PubMed
    Score: 0.157
  5. Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis. Exp Cell Res. 2016 Jan 15; 340(2):305-14.
    View in: PubMed
    Score: 0.079
  6. Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. Sci Rep. 2015 Jul 22; 5:12463.
    View in: PubMed
    Score: 0.076
  7. Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells. J Am Heart Assoc. 2014 Sep 18; 3(5):e001194.
    View in: PubMed
    Score: 0.072
  8. Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Lab Invest. 2013 May; 93(5):577-91.
    View in: PubMed
    Score: 0.065
  9. Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol. 2010 Nov; 299(5):H1419-27.
    View in: PubMed
    Score: 0.054
  10. Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension. 2008 Oct; 52(4):715-20.
    View in: PubMed
    Score: 0.047
  11. Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther. 2008 Aug; 19(8):807-19.
    View in: PubMed
    Score: 0.047
  12. Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul Pept. 2007 Apr 05; 140(1-2):12-20.
    View in: PubMed
    Score: 0.042
  13. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther. 2006 Dec; 17(12):1201-13.
    View in: PubMed
    Score: 0.042
  14. Experimental therapy with tissue kallikrein against cerebral ischemia. Front Biosci. 2006 May 01; 11:1323-7.
    View in: PubMed
    Score: 0.040
  15. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther. 2006 Feb; 17(2):206-19.
    View in: PubMed
    Score: 0.040
  16. Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant. 2006 Mar; 21(3):624-33.
    View in: PubMed
    Score: 0.040
  17. Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. J Biol Chem. 2005 Mar 04; 280(9):8022-30.
    View in: PubMed
    Score: 0.037
  18. Adrenomedullin gene delivery protects against cerebral ischemic injury by promoting astrocyte migration and survival. Hum Gene Ther. 2004 Dec; 15(12):1243-54.
    View in: PubMed
    Score: 0.037
  19. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension. 2004 Feb; 43(2):452-9.
    View in: PubMed
    Score: 0.034
  20. Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. Hypertension. 2004 Jan; 43(1):109-16.
    View in: PubMed
    Score: 0.034
  21. Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1506-14.
    View in: PubMed
    Score: 0.033
  22. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension. 2000 Jan; 35(1 Pt 1):25-31.
    View in: PubMed
    Score: 0.026
  23. Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology. 2014 Jun; 142(2):216-26.
    View in: PubMed
    Score: 0.018
  24. Tissue kallikrein-modified mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction. Circ J. 2013; 77(8):2134-44.
    View in: PubMed
    Score: 0.016
  25. Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury. Toxicol Sci. 2008 Apr; 102(2):433-43.
    View in: PubMed
    Score: 0.011
  26. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology. 2007 May; 148(5):2016-26.
    View in: PubMed
    Score: 0.011
  27. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension. 2006 Apr; 47(4):752-61.
    View in: PubMed
    Score: 0.010
  28. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci. 2005 Apr 08; 76(21):2457-71.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.